Valeant raises 2015 adjusted profit outlook more than expected
Jan 8 (Reuters) - Valeant Pharmaceuticals International Inc said on Thursday that it expected in 2015 to reap revenue of $9.2 billion to $9.3 billion and cash earnings of $10.10 to $10.40 per share, exceeding last year's results.
Analysts on average estimated $10.05 in cash earnings, or adjusted profit, and $9.03 billion in revenue, according to Thomson Reuters I/B/E/S. Valeant had previously targeted $10 in cash earnings per share and $9.1 billion in revenue.
(Reporting by Rod Nickel in Winnipeg, Manitoba; Editing by Chizu Nomiyama)
Terms and Privacy Policy